Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma
In conclusion, our results demonstrate that MALAT1 may serve as a novel prognostic biomarker and an ideal therapeutic target for patients with PGI-DLBCL.
Source: Clinical and Experimental Medicine - Category: Research Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Lymphoma | Research | Study